Prevention of adrenaline-induced metabolic systemic and myocardial alterations by the beta-blocking agent metipranolol in the dog.
We investigated the effectiveness of the beta-blocking agent metipranolol in preventing detrimental systemic and myocardial alterations induced in healthy dogs by adrenaline (AD) infused at a rate which mimics spontaneous secretion after coronary occlusion. Metipranolol (0.3 mg/kg) was infused intravenously concurrently with AD (1.2 micrograms/kg/min) for 4 h and blood values of free fatty acids (FFA) and triiodothyronine(T3) were measured initially, after 2 and 4 h of infusion and compared with those obtained in dogs infused with AD alone and with saline. Metipranolol suppressed a rise in free fatty acid, reversed AD-induced histoenzymatic changes in succinic dehydrogenase and ATPase activity and considerably inhibited the development of mitochondrial alterations detected in dogs infused with AD alone. A tendency to attenuate AD-induced fall in serum T3 was also detected in metipranolol-treated dogs. Results suggest that this drug might be of value in preventing consequences of increased adrenergic activity in the acute stage of myocardial infarction.
D000251:Adenosine Triphosphatases / Q000378:metabolism; D000818:Animals; D003327:Coronary Disease / Q000517:prevention & control*; D004285:Dogs; D004837:Epinephrine / Q000494:pharmacology*; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005260:Female; D006321:Heart / Q000187:drug effects; D006863:Hydrogen-Ion Concentration; D008297:Male; D008660:Metabolism / Q000187:drug effects*; D014290:Metipranolol / Q000627:therapeutic use*; D009206:Myocardium / Q000378:metabolism / Q000648:ultrastructure; D011412:Propanolamines / Q000627:therapeutic use*; D013385:Succinate Dehydrogenase / Q000378:metabolism; D014284:Triiodothyronine / Q000097:blood
D005230:Fatty Acids, Nonesterified; D011412:Propanolamines; D014284:Triiodothyronine; D013385:Succinate Dehydrogenase; D000251:Adenosine Triphosphatases; D014290:Metipranolol; D004837:Epinephrine